Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 10, No 4 (2017) INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW Abstract  similar documents
D. G. Tolkacheva, A. V. Torgov, A. S. Margazova
"... of the reviewed countries have policies controlling prices for generic drugs and employ the internal reference ..."
 
Vol 10, No 4 (2017) INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW Abstract  similar documents
D. G. Tolkacheva, A. V. Torgov, A. S. Margazova
"... of the reviewed countries have policies controlling prices for generic drugs and employ the internal reference ..."
 
Vol 10, No 4 (2017) IMPROVEMENT OF PRICE REGULATION FOR INNOVATIVE MEDICINES COVERED BY THE NATIONAL BUDGET Abstract  similar documents
V. A. Lemeshko, N. Z. Musina, V. K. Fedyaeva
"... the therapeutic value of the drug into its consumer price. The drug pricing system existing in the Russian ..."
 
Vol 13, No 2 (2020) Review of calculation methods, procedures for registration and re-registration of producer prices of medicines in the countries of the Eurasian Economic Union Abstract  similar documents
A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich
"... normative legal acts (NLA) in the sphere of price formation on pharmaceutical drugs in the EAEC. The study ..."
 
Vol 15, No 1 (2022) Study of methods for state regulation of prices and costs of the health care system for medicines in the United Kingdom Abstract  similar documents
A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich
"... Objective: analysis of state regulation of prices and costs for the purchase of medicines (drugs ..."
 
Vol 7, No 4 (2014) ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentieva
"... drug supply (comprehensive drug reimbursement system) and reference pricing. The analysis of prices ..."
 
Vol 10, No 2 (2017) THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS Abstract  similar documents
V. K. Fedyaeva, V. V. Omelyanovskiy, N. Z. Musina, G. R. Khachatryan, O. I. Ivakhnenko
"... Among the most important aspects of the health policy are the methods for pricing of medicines ..."
 
Vol 7, No 4 (2014) IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? Abstract  similar documents
V. V. Omelyanovskiy
"... the analysis of foreign pricing and drug supply public funding systems (or a so-called drug ..."
 
Vol 12, No 2 (2019) Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available Abstract  similar documents
F. V. Gorkavenko, A. V. Nikitina, E. S. Saibel’, M. V. Avksent’eva, M. V. Sura, D. V. Fedyaev
"... trends in the general picture of drug prices and consumption. In the present study, we analyze ..."
 
Vol 14, No 2 (2021) Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price Abstract  similar documents
D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov
"... of oral vinorelbine was carried out taking into consideration the change in the price of the drug ..."
 
Vol 17, No 4 (2024) Regional aspects of availability of expectorants and antitussive drugs Abstract  similar documents
V. М. Timiryanova, А. V. Samorodov, Z. А. Valiullina, V. B. Prudnikov, D. Kh. Krasnoselskaya
"... differentiation in the availability of individual drugs and their price levels, which determines the variability ..."
 
Vol 10, No 2 (2017) COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS Abstract  similar documents
M. B. Kubaeva, Y. Sh. Guchshina
"... of anti-HIV drugs. Material and methods. The study was based on the documented medical histories of HIV ..."
 
Vol 17, No 1 (2024) Analysis of the availability of bronchodilators and anti-inflammatory drugs for patients with chronic obstructive pulmonary disease Abstract  PDF (Eng)  similar documents
E. A. Orlova, V. I. Petrov, I. P. Dorfman, O. V. Shatalova, M. A. Orlov
"... in the Russian Federation. Objective: to assess drug prices, affordability, and availability for COPD patients ..."
 
Vol 15, No 1 (2022) The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies Abstract  similar documents
A. S. Kolbin, Yu. M. Gomon, A. R. Kasimova, A. A. Kurylev, A. E. Bem
"... research with the requirements applicable in the Russian Federation (RF) when including drugs ..."
 
Vol 17, No 4 (2024) Pharmacoeconomic study of active psoriatic arthritis treatment Abstract  similar documents
A. V. Rudakova, Т. V. Korotaeva
"... biological (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs), available ..."
 
Vol 7, No 4 (2014) ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY Abstract  similar documents
D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky
"... drugs, the level of price reduction as a result of trading, the amount and volume of purchases ..."
 
Vol 14, No 2 (2021) Analysis of the availability and affordability of pharmaceuticals for children in need of palliative care Abstract  similar documents
D. M. Medvedeva, I. A. Narkevich, O. D. Nemyatykh
"... of palliative care. Materials and methods. The price, affordability and physical availability ..."
 
Vol 8, No 3 (2015) COMPARATIVE PHARMACOECONOMIC STUDY OF VITAMIN-MINERAL COMPLEXES FOR REHABILITATION DURING THE PERIOD OF INCREASED NEEDS FOR MICRONUTRIENTS Abstract  similar documents
A. Yu. Belinskaya, I. Yu. Torshin, T. R. Grishina, O. A. Gromova
"... data VEC to 127 regions of Russia formulated price categories of drugs and the analysis of available ..."
 
Vol 9, No 1 (2016) MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 Abstract  similar documents
A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum
"... Background: In 2014 we firstly analyzed the formalized system (points and expert opinions) of drug ..."
 
Vol 9, No 3 (2016) EARLY HEALTH TECHNOLOGIES ASSESSMENT — NEW APPROACH TO IMPROVING THE EFFICIENCY OF THE MEDICAL TECHNOLOGY DEVELOPMENT PROCESS Abstract  similar documents
N. Z. Musina, V. V. Omelyanovskiy, A. V. Krasheninnikova
"... trials, to predict the probability of formulary inclusion, and to define socially acceptable price. ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... of orphan drugs and to carry out state regulation of prices, to ensure increase of regional funding ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... . The costs in model are calculated on the basis of registered prices on drugs from the List of vital ..."
 
Vol 10, No 2 (2017) PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY Abstract  similar documents
A. V. Rudakova, S. A. Protsenko, I. A. Koroleva
"... on pricing entered with no discounts for a period of 1-5 years. The costs of the immunotherapeutic drugs were ..."
 
Vol 14, No 4 (2021) Features of intellectual property protection mechanisms on the example of orphan drugs circulation Abstract  similar documents
D. S. Yurochkin, К. V. Nasonova, Z. М. Golant, I. А. Narkevich, V. P. Trukhin
"... of drugs for the treatment of rare (orphan) diseases. Material and methods. Analysis of pharmaceutical ..."
 
Vol 9, No 2 (2016) MANAGEMENT ASPECT OF THE PROBLEM OF NARCOTIC DRUGS USE Abstract  similar documents
S. Yu. Soboleva, A. V. Sobolev, I. A. Kaminskaya
"... The use of narcotic drugs in healthcare system nowadays is characterized by lawful aspects ..."
 
Vol 17, No 4 (2024) Pharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system Abstract  similar documents
A. V. Rudakova, I. Z. Gaydukova
"... spondylitis (AS) in comparison with other biological disease-modifying antirheumatic drugs (bDMARDs) currently ..."
 
Vol 14, No 2 (2021) Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting Abstract  similar documents
E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov
"... Background. The introduction of innovative drugs has significantly increased the treatment ..."
 
Vol 17, No 1 (2024) Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer Abstract  similar documents
S. К. Zyryanov, I. N. Dyakov
"... + carboplatin” drug combination compared to “pembrolizumab + pemetrexed + carboplatin” combination in adult ..."
 
Vol 13, No 4 (2020) Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia Abstract  similar documents
V. G. Deriushkin, A. P. Ternavskii, S. V. Gatsura
"... The study aimed to perform a pharmacoeconomic analysis of antimicrobial drugs (AMDs) prescribed ..."
 
Vol 16, No 2 (2023) Development of methodological approaches to the formation of a risk-based model to minimize the prevalence of adverse reactions in drug application in medical organizations of Moscow Abstract  similar documents
E. V. Kuznetsova, M. V. Zhuravleva, I. A. Mikhailov, T. I. Kurnosova
"... using drugs based on a comprehensive assessment of risk factors. Material and methods. We used ..."
 
Vol 17, No 1 (2024) STEP analysis of macro-environmental factors affecting medical and drug care for patients with chronic myeloid leukemia Abstract  similar documents
A. V. Zhuravlev, O. I. Knysh
"... -environmental factors influencing medical and drug care for patients with chronic myeloid leukemia (CML ..."
 
Vol 17, No 4 (2024) Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment Abstract  similar documents
S. К. Zyryanov, I. N. Dyakov
"... results of phase III clinical trials and clinical guidelines. Drug pricing information was derived from ..."
 
Vol 10, No 3 (2017) Review of the current approaches to the assessment of the drug innovative potential worldwide Abstract  similar documents
N. Z. Musina, V. K. Fedyaeva, V. V. Omel’yanovskii, G. R. Khachatryan, K. V. Gerasimova, V. A. Lemeshko, K. P. Konchits
"... A set of criteria for assessing the innovative potential of drugs (therapeutic value) have been ..."
 
Vol 18, No 1 (2025) The sale of medicines used for diabetes mellitus treatment in retail segment of Russian pharmaceutical market Abstract  similar documents
I. K. Petrukhina, A. M. Lazarev, T. K. Ryazanova, P. A. Lebedev, E. P. Gladunova, G. T. Glembotskaya
"... period, the weighted average price (WAP) per 1 package of a drug for DM treatment increased from 472 ..."
 
Vol 16, No 2 (2023) Improving the model of payment for medical care for chronic viral hepatitis C in the framework of the implementation of the Program of State Guarantees of Free Provision of Medical Care to Citizens for 2023 and for the planned period of 2024–2025 Abstract  similar documents
V. V. Omelyanovskiy, I. A. Zheleznyakova, A. V. Zuev, O. S. Plakhotnik, O. A. Volkova, L. M. Davydova, G. V. Trifonova, E. V. Semakova, E. A. Prokhorovich, A. S. Volkova
"... ) in adults were published that did not contain interferon drug therapy regimens. Current therapy of chronic ..."
 
Vol 15, No 2 (2022) The current state of the veterinary drugs market in the Tyumen Region Abstract  similar documents
V. V. Byshenko, О. I. Knysh, L. N. Zadirachenko, А. О. Egorova, Yu. S. Rodina
"... clinics in the Tyumen Region (33); price lists of veterinary pharmaceutical organizations; questionnaires ..."
 
Vol 18, No 2 (2025) Marketing analysis of the Russian pharmaceutical market for treatment of neovascular age-related macular degeneration Abstract  similar documents
F. V. Gorkavenko, A. B. Goryachev, O. V. Ashikhmina, D. V. Fedyaev, N. V. Ignateva, E. A. Smolyarchuk, A. V. Kirchenko, D. D. Tkachenko, V. I. Brazhnikova
"... for the studied group of drugs were accompanied by an increase in weighted average prices and a growing share ..."
 
Vol 17, No 3 (2024) Assessment of the impact of procurement centralization on the drug provision for patients within the High-Cost Nosology Program in the Russian Federation Abstract  similar documents
V. V. Omelyanovskiy, V. A. Ryagina, A. G. Kharitonova, K. I. Matrenin, A. A. Kingshott, O. V. Ashikhmina, M. V. Zhirov
"... centralization on the weighted average price (WAP) per 1 unit of measurement (UM) of a drug, the procurement ..."
 
Vol 12, No 3 (2019) Pharmacoepidemiological analysis of antimicrobial therapy for burn injury in the hospital settings Abstract  similar documents
O. V. Zhukova, E. S. Nekaeva, E. S. Khoroshavina, E. A. Kozlova, Yu. A. Dudukina, I. Yu. Arefyev
"... than other drugs because of its high efficacy in the hospital settings and its low price. We found ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... to be included in the VED, for now the drug has no quoted price. Therefore, we used the price suggested ..."
 
Vol 16, No 1 (2023) Compounding pharmacy regulations: experience of the North American pharmaceutical market Abstract  similar documents
D. D. Mamedov, D. S. Yurochkin, A. A. Leshkevich, S. E. Erdni-Garyaev, Z. M. Golant, I. A. Narkevich
"... requirements for ensuring quality and safety of compounding drugs, as well as historical and technical analysis ..."
 
Vol 13, No 2 (2020) Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871 Abstract  similar documents
V. V. Omelyanovskiy, E. A. Maksimkina, O. I. Ivakhnenko, M. V. Avxentyeva, M. V. Sura, G. R. Khachatryan
"... development of approaches for complex drug assessment in Russia, also criteria for its evaluation were under ..."
 
Online First Osteoarthritis therapy misconcepts Abstract  similar documents
O. A. Shavlovskaya, О. А. Gromova, I. Yu. Torshin, I. D. Romanov
"... , as new molecules appear, data concerning drugs/molecules that are already in use, appear as well ..."
 
Vol 16, No 2 (2023) From misconceptions to reasonable osteoarthritis patients therapy Abstract  similar documents
O. A. Shavlovskaya, О. А. Gromova, I. Yu. Torshin, I. D. Romanov
"... revised, as new molecules appear, data on drugs/molecules already in use, including data on adverse events ..."
 
Vol 17, No 3 (2024) Differential chemoproteomic analysis of RRS-1 candidate molecule and molecules of several nonsteroidal anti-inflammatory drugs Abstract  similar documents
P. A. Galenko-Yaroshevsky, I. Yu. Torshin, A. N. Gromov, O. A. Gromova, K. F. Suzdalev, R. A. Murashko, A. V. Zelenskaya, A. V. Zadorozhniy, T. R. Glechyan, G. V. Simavonyan, E.M. I. Muhammad
"... to evaluate the mechanisms and spectrum of action of nonsteroidal anti-inflammatory drugs (NSAIDs), including ..."
 
Vol 18, No 1 (2025) Analysis of methotrexate use practice in patients with rheumatoid and psoriatic arthritis Abstract  similar documents
S. A. Doktorova, Yu. Yu. Grabovetskaya, A. V. Zuev, J. N. Aksenova-Sorokhtei, V. V. Rafalskiy
"... antirheumatic drugs. The current therapeutic concept for these conditions focuses on achieving and maintaining ..."
 
Vol 18, No 1 (2025) Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia Abstract  similar documents
A. Yu. Efremov, A. M. Vlasov, V. I. Gegechkori, N. V. Gorpinchenko, G. V. Ramenskaya, T. M. Litvinova
"... and marketing methods, including normalization of drug costs to weighted average prices (rub/mg), ABC analysis ..."
 
Vol 10, No 2 (2017) COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov
"... regimens were calculated from the registered data on the maximum selling prices of VED drugs or from ..."
 
Vol 11, No 4 (2018) Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer Abstract  similar documents
N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov
"... direct medical costs (price of the drugs) of using enzalutamide or abiraterone for treatment ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... Orphan drugs are used for treatment of rare life-threatening diseases. There is no universal ..."
 
1 - 50 of 325 Items 1 2 3 4 5 6 7 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)